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Introduction: Radiation-induced pneumonitis and fibrosis have 
restricted radiotherapy for lung cancer. In a preclinical lung tumor 
model, soy isoflavones showed the potential to enhance radiation 
damage in tumor nodules and simultaneously protect normal lung 
from radiation injury. We have further dissected the role of soy iso-
flavones in the radioprotection of lung tissue.
Methods: Naive Balb/c mice were treated with oral soy isoflavones 
for 3 days before and up to 4 months after radiation. Radiation was 
administered to the left lung at 12 Gy. Mice were monitored for toxic-
ity and breathing rates at 2, 3, and 4 months after radiation. Lung tis-
sues were processed for histology for in situ evaluation of response.
Results: Radiation caused damage to normal hair follicles, leading 
to hair loss in the irradiated left thoracic area. Supplementation with 
soy isoflavones protected mice against radiation-induced skin injury 
and hair loss. Lung irradiation also caused an increase in mouse 
breathing rate that was more pronounced by 4 months after radia-
tion, probably because of the late effects of radiation-induced injury 
to normal lung tissue. However, this effect was mitigated by soy 
isoflavones. Histological examination of irradiated lungs revealed a 
chronic inflammatory infiltration involving alveoli and bronchioles 
and a progressive increase in fibrosis. These adverse effects of radia-
tion were alleviated by soy isoflavones.
Conclusion: Soy isoflavones given pre- and postradiation protected 
the lungs against adverse effects of radiation including skin injury, 
hair loss, increased breathing rates, inflammation, pneumonitis and 
fibrosis, providing evidence for a radioprotective effect of soy.
Key Words: Soy, Radiation, Lung, Protection.
(J Thorac Oncol. 2013;8: 1356–1364)
Radiotherapy for non–small-cell lung cancer (NSCLC) is limited by radiation toxicity to normal lung tissue, which 
results from an inflammatory process caused by damage to 
capillary endothelial cells and epithelial lung cells causing 
pneumonitis and fibrosis.1–4
We are exploring the potential for biological/nutritional 
intervention using soy isoflavones to boost the success of radio-
therapy and decrease its toxicity in NSCLC. This complemen-
tary approach could benefit patients with compromised lung 
functions including chronic obstructive pulmonary disease 
in smokers and patients with larger or nonperipheral tumors, 
such as unresectable stage III locally advanced NSCLC, in 
which radiotherapy is limited by anticipated toxicity.1 Soy 
isoflavones are nontoxic dietary plant estrogens extracted 
from soy beans and anticancer agents, as demonstrated in 
controlled clinical trials.5 They can also act as antioxidants 
in normal tissues and protect them from treatment-induced 
toxicity.6 This protective effect was observed in our clinical 
trial for prostate cancer patients, showing that soy isoflavone 
pills, taken in conjunction with radiotherapy, reduced radia-
tion toxicity, resulting in improved urinary, gastrointestinal, 
and sexual functions.6
The rationale for selecting soy isoflavones to combine 
with radiotherapy for NSCLC is based on our work demon-
strating that these compounds have a differential effect on 
tumor versus normal tissue. In contrast to normal cells, critical 
survival pathways are constitutively activated in cancer cells, 
including DNA-repair molecules, the nuclear factor-κB, and 
hypoxia-inducible factor-1α transcription factors, which are 
responsible for promoting malignant behavior by transcrip-
tion of proteins involved in tumor progression. These survival 
pathways are further up-regulated in response to radiation and 
thereby, are implicated in radioresistance of cancer. We have 
consistently shown that soy isoflavones inhibited radiation-
induced up-regulation of these survival pathways resulting 
in greater cancer destruction both in vitro and in vivo, using 
orthotopic models of lung carcinoma, renal cell carcinoma, 
and prostate cancer.7–14 In particular, in lung cancer studies, 
we previously reported that soy isoflavones enhanced radia-
tion-induced cell killing of human NSCLC cells in vitro by 
increasing DNA damage and inhibiting DNA repair in addi-
tion to inhibiting nuclear factor-κB and hypoxia-inducible 
factor-1α.12 In contrast, normal cells do not express such acti-
vated malignant survival pathways and thus, are not affected 
directly by soy isoflavones. In normal tissues, radiation causes 
tissue damage, resulting in inflammatory processes leading 
to pneumonitis and fibrosis. Initial studies suggested that soy 
inhibited the progression of radiation-induced inflammatory 
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events in normal lung tissue. In an orthotopic murine model 
of lung cancer, soy isoflavones increased radiation-induced 
destruction of lung tumor nodules, but also mitigated the vas-
cular damage, inflammation, and fibrosis caused by radiation 
injury to lung tissue.7 These studies suggested that soy iso-
flavones have the dual potential to enhance radiation damage 
in lung tumors and simultaneously protect normal lung from 
radiation injury.
To evaluate further the role of soy isoflavones in mod-
erating adverse effects of radiation on lung tissue, we have 
now investigated the effect of soy isoflavones on the damage 
caused by a high-radiation dose in normal lung in naive mice 
not bearing tumors. These conditions were selected to detect 
significant tissue damage by high-radiation doses, which have 
been shown to result in greater toxicity in clinical studies.15 
We report that supplementation with soy isoflavones pre- 
and postradiation clearly attenuated skin injury and hair loss 
caused by radiation, a cogent evidence for the radioprotective 
effect of soy isoflavones on normal tissues. Furthermore, soy 
isoflavones protected mice from radiation-increased breath-
ing rate. Histological observation of lung tissues confirmed 
that soy isoflavones protected normal lung structures against 
radiation-induced inflammation, damage, and fibrosis.
MATERIALS AND METHODS
Mice
Female Balb/c mice that were 5 to 6 weeks old (Harlan, 
Indianapolis, IN) were housed and handled in animal facili-
ties accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care. The animal pro-
tocol was approved by Wayne State University Institutional 
Animal Care and Use Committee.
Soy Isoflavones
The soy isoflavones mixture G-4660 used is a pure 
extract of 98.16% isoflavones from soybeans consisting of 
83.3% genistein, 14.6% daidzein, and 0.26% glycitein (manu-
factured by Organic Technologies and obtained from National 
Institutes of Health, Bethesda, MD). The soy isoflavones mix-
ture was dissolved in 0.1 mol/liter Na
2
CO
3
 and mixed with 
sesame seed oil at a 2:1 ratio just before treatment to facili-
tate gavage and avoid irritation of the esophagus by Na
2
CO
3
.7 
Mice were orally treated with 5 or 1 mg/day of soy isoflavones 
(250 or 50 mg/kg body weight/day) by gavage. Control mice 
received the vehicle alone.
Lung Irradiation
Radiation was delivered to the left lobe of the lungs. 
Three anesthetized mice, in jigs, were positioned under a 
6.4-mm lead shield with three cutouts in an aluminum frame 
mounted on the radiograph machine to permit selective irra-
diation of the left lung in three mice at a time, as previously 
described.7 The radiation dose to the lung and the scattered 
dose to areas of the mouse outside of the radiation field were 
carefully monitored. To minimize backscattering of radiation, 
the bottom of the aluminum frame that holds the jigs was hol-
lowed out and the backplate of the jig was thinned to 1.6-mm 
thickness. Under these conditions and the lead shielding, the 
radiograph dose to the shielded regions was reduced to 1% of 
the dose to the irradiated field. The dose rate was 101.0 cGy/
minute and half value layer was 2-mm Cu. Photon irradiation 
was performed at a dose of 12 Gy with a Siemens Stabilipan 
X-ray set (Siemens Medical Systems, Inc., Erlangen, 
Germany) operated at 250 kV, 15 mA with 1-mm copper fil-
tration at a distance of 47.5 cm from the target.
Experimental Protocol
Mice were pretreated with oral soy isoflavones each day 
for 3 days at a dose of 5 mg/day (equivalent to 250 mg/kg). 
Then, the left lung was selectively irradiated with 12 Gy. Soy 
treatment was continued on a daily basis for 5 more days at 
5 mg/day. Then mice were treated with a lower dose of 1 mg/
day (equivalent to 50 mg/kg), given daily 5 days a week for 
up to 18 weeks. The rationale for giving a higher dose of soy 
isoflavones for pretreatment and just after radiation was opti-
mization of the effect of soy, based on previous studies.8,10
Hair Loss Monitoring of Mice Treated with 
Soy Isoflavones and Lung Irradiation
Mice were treated with soy isoflavones and left lung 
irradiation as described above (see Experimental Protocol 
section). After radiation, mice were treated with soy given 
daily, 5 days a week, for 5 more weeks. Four experimental 
treatment groups consisting of 13 mice per group included 
control mice treated with vehicle alone, mice treated with soy 
alone, mice treated with radiation alone and mice treated with 
soy and radiation. Mice were monitored three times a week 
for signs of radiation-induced injury. The area showing hair 
loss was measured in two dimensions. Hair loss in the radi-
ated field was scored at 100% for bare skin, to 75%, 50%, and 
25% based on the density of hair and the size of area showing 
hair loss.
Breathing Rate Measurements of Mice Treated 
with Soy Isoflavones and Lung Irradiation
Mice were treated with soy isoflavones and left lung 
irradiation as described above (see Experimental Protocol 
section). After radiation, mice were treated with soy given 
daily, 5 days a week, for up to 18 weeks. Four experimental 
treatment groups consisting of eight mice per group included 
control mice treated with vehicle alone, mice treated with 
soy alone, mice treated with radiation alone, and mice 
treated with soy and radiation. Mice were monitored for 
up to 4 to 5 months and their breathing rate was measured 
using a mouse CollarClip Sensor according to manufactur-
er’s instructions (STARR Life Sciences, Corp., Oakmont, 
PA).16–18 The breathing rate of eight mice per treatment 
group was measured at late time points of about 2, 3, and 4 
months (days 59, 86, and 130) after radiation. Data were col-
lected on conscious mice during 10 minutes for each mouse. 
Breathing rates were measured when mice were relatively 
calm and no error code was shown on the instrument.16 These 
rates were computed to estimate the average breathing rate 
of each mouse.
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Lung Tissue Preparation for Histological  
Examination
Mice were treated with soy isoflavones and left lung 
irradiation as described above (see Experimental Protocol 
section). After radiation, mice were treated with soy given 
daily, 5 days a week, for up to 18 weeks. At different time 
points, mice were killed and lungs were perfused with 10% 
buffered formalin for fixation in situ. The lungs were resected 
and the irradiated left lung and the nonirradiated right lung 
were processed separately for paraffin embedding and sec-
tioning.7 Sections were stained with hematoxylin and eosin. 
The extent of fibrosis was evaluated by staining lung sec-
tions with Masson’s Trichrome (NovaUltra Kit; IHCWORLD, 
Woodstock, MD).7,19 The extent of lung damage, inflammatory 
infiltration, pneumonitis, and fibrosis were quantified using a 
scoring system on a scale from weak (±),moderate (+), strong, 
(++) to heavy (+++).
Statistical Analysis
For histological data analysis, differences in the sur-
face area of hair loss and breathing rates among the vari-
ous treatments groups were analyzed by two-tailed unpaired 
Student’s t test.
RESULTS
Cogent Evidence Demonstrating 
Radioprotection by Soy Isoflavones: 
Decrease in Radiation-Induced Hair Loss
To determine whether soy isoflavones could protect nor-
mal lung tissues from radiation-induced damage, mice were 
treated with radiation alone or combined with soy isoflavones 
for up to 7 weeks, as detailed in Materials and Methods sec-
tion. Mice were monitored daily for signs of toxicity. We 
observed hair loss in the left upper thoracic side, which had 
been irradiated. Hair loss was scored as 100%, 75%, 50%, 
and 25% in the irradiated area based on the size of the injured 
area and the hair density (Fig. 1). For example, in mice treated 
with radiation alone, a mouse with bared skin was scored as 
having 100% hair loss and most of the mice showed 50% to 
75% hair loss (Fig. 1A). In contrast, a large number of mice 
in the experimental group treated with soy isoflavones before 
and after radiation showed 0% to 25% hair loss (Fig. 1B). The 
proportion of mice with significant hair loss in the radiation 
group was 13 of 13 mice, with 92% of the mice showing 50% 
or greater hair loss (Fig. 2A). However, in the experimental 
group treated with soy isoflavones and radiation, only six of 
13 mice had measurable hair loss, mostly in the range of 25% 
(Fig. 2A). Kinetics experiments showed that hair loss appeared 
as early as 3 weeks after radiation and all mice showed hair 
loss by 5 weeks after radiation (Fig. 2B). The surface area with 
hair loss progressively increased with time in all mice treated 
with radiation only (Fig. 2B). However, the kinetics of hair 
loss were much slower in mice treated with radiation com-
bined with soy isoflavones beginning at 4 to 6 weeks after ini-
tiation of soy treatment (Fig. 2C). The surface area of hair loss 
was also significantly smaller by 5 to 6 weeks compared with 
that of mice treated with radiation alone (p < 0.01; Fig. 2C).
Soy Isoflavones Mitigated the Increased 
Breathing Rate Induced by Radiation
Lung tissue injury induced by radiotherapy leads to 
an inflammatory process that results in pneumonitis and 
fibrosis.20,21 The presence of fibrosis in lung tissues leads to 
FIGURE 1.  Hair loss in irradiated 
thoracic area of mice treated with 
radiation or radiation combined 
with soy isoflavones. A, Hair loss 
induced by radiation. Mice received 
12 Gy radiation to the left lung. B, 
Protection against radiation-induced 
hair loss by soy isoflavones. Mice 
were treated with soy isoflavones 
and 12 Gy radiation administered to 
the left lung. Soy was given 3 days 
before radiation and continued 5 
days a week after radiation. At about 
7 weeks after initiation of soy treat-
ment, hair loss was scored from 0% 
to 100% as shown in yellow numbers 
on the bottom left of each mouse 
picture. Eight representative mice per 
treatment group are shown.
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difficulties in breathing, which cause increased breathing rate 
and these late effects of radiation toxicity occur in patients 
several months after radiation.3,22 Increase in breathing rates 
was also documented in mice or rats treated with lung irradia-
tion.2,23–25 To evaluate the effect of soy isoflavones on breathing 
rates altered by radiation, we have measured the breathing rate 
of mice treated with lung irradiation, soy isoflavones, and both 
combined. An increase in the breathing rate of mice receiving 
only lung irradiation was noticed by days 59 and 86 (Fig. 3). 
The increased breathing rates were significantly more pro-
nounced by 4 months (day 130) after radiation with a mean of 
209 ± 19 breaths/minute compared with 170 ± 8 breaths/minute 
in control mice (p < 0.001), probably because of the late effects 
of radiation injury to lung tissue (Fig. 3). However, this effect 
was mitigated by supplementation with soy isoflavones pre- and 
postradiation, causing a breathing rate in the lower range of 
168 ± 5 breaths/minute (p < 0.001; compared with radiation) 
that was comparable with that of untreated control mice (Fig. 3).
Histological Observations in Lungs Treated 
with Soy Isoflavones and Radiation
To assess in situ the effect of soy isoflavones and left lung 
irradiation on lung tissue structures, both the left lung and the 
right lung were separately resected at about 2, 3, and 4 months 
after treatment with either therapy alone or both combined 
and processed for histology studies. At all time points, lungs 
from control mice showed normal blood vessels with integral 
basement membrane, endothelial lining with endothelial cells 
surrounded by normal alveoli (Fig. 4A1). Normal structures 
of bronchioles lined by ciliated columnar epithelium and 
FIGURE 2.  Kinetics of hair loss in irradiated thoracic area of mice treated with radiation combined with soy isoflavones. Mice 
were treated either with 12 Gy radiation administered to the left lung alone or combined with soy isoflavones treatment. Soy 
was given 3 days before radiation and continued 5 days a week after radiation. A, Hair loss scoring in mice treated with radia-
tion or radiation and soy isoflavones. At about 7 weeks after initiation of soy treatment, hair loss was scored from 0% to 100% 
based on the density of hair and the size of area showing hair loss. The proportion of mice with hair loss is based on 13 mice 
per treatment group (inserted in text box). B and C, Kinetics of hair loss after radiation (B) or radiation combined with soy iso-
flavones treatment (C). Mice were monitored for hair loss three times a week after initiation of treatment. The area showing hair 
loss was measured in two dimensions and the surface area was plotted. Each dot in A, B, and C represent one mouse.
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surrounded by normal thin alveolar septa were seen (Fig. 4A2, 
A3; Table 1). After treatment with soy isoflavones at 2, 3, and 4 
months, the structures of blood vessels (Fig. 4B1, B2), bronchi-
oles and the thickness of alveolar were not altered and looked 
normal compared with that of untreated lungs (Fig. 4B1–B3; 
Table 1). In contrast, radiation to the left lung caused signifi-
cant tissue damage, which was clearly observed on day 64 
and further increased at the later time points of day 87 and 
134 (Table 1). The alveolar septa and vessel walls showed a 
chronic inflammatory infiltrate indicative of pneumonitis, 
causing a marked reduction in alveolar spaces compared with 
control or soy-treated lungs (Fig. 4C1–C3; Table 1). Clusters 
of inflammatory cells were observed in the vicinity of blood 
vessels and infiltrating into the alveoli (Fig. 4C1, C3 and C1A, 
C3A), disrupting the integrity of the vessel wall (Fig. 4C2). 
Focal areas of damaged alveolar tissues were replaced by a 
heavy infiltration of inflammatory infiltrates consisting mostly 
of histiocytes and lymphocytes (Fig. 4C2 and C2A; Table 1). 
Focal hemorrhages were seen, likely the result of vascular 
damage induced by radiation. These data suggest that radia-
tion caused a long-lasting and strong inflammatory response 
that became even more prominent by 4 months after radiation. 
These findings were not observed in nonirradiated right lungs 
of these mice. Irradiated left lungs from mice treated with soy 
isoflavones before and after radiation showed mostly normal 
bronchioles, alveoli, and blood vessels with minimal inflam-
matory infiltrate and hemorrhage showing milder pneumonitis 
compared with radiation-treated lungs (Fig. 4D1–D3; Table 1).
FIGURE 3.  Breathing rate of mice treated with soy and radiation. Mice were treated either with soy or 12 Gy radiation (Rad) 
administered to the left lung alone or soy isoflavones combined with radiation (Soy + Rad). Soy was continued 5 days a week 
for up to 18 weeks. The breathing rate of eight mice per treatment group was measured on day 59, 86, and 130 after initiation 
of soy treatment. Each dot represents the average breathing rate value obtained from one mouse (n = 8 per group).
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Detection of Fibrosis in Lungs 
Treated with Soy and Radiation
We have documented above the occurrence of radiation-
induced pneumonitis as well as the beneficial effects of soy 
supplementation. Because pneumonitis is associated with 
development of fibrosis,4,20 the effect of soy isoflavones on 
this late event was also evaluated by staining collagen fibers 
with the Masson’s trichrome stain. The lungs from control and 
soy-treated mice showed typical light blue staining of colla-
gen fibers around vessels and bronchioles (Fig. 5A1, A2 and 
FIGURE 4.  H&E staining of lung 
tissue sections from mice treated 
with soy, radiation, and radiation + 
soy. Mice were treated either with 
soy or 12 Gy radiation (Rad) admin-
istered to the left lung alone or soy 
isoflavones combined with radiation 
(Soy + Rad). Soy was continued 5 
days a week for up to 19 weeks. Lung 
tissue sections obtained on days 64, 
87, and 134 after radiation were 
processed for H&E staining. A1–3, 
Control lung from untreated mice 
showing normal structures of lung 
tissues including vessels (V), bron-
chioles (BR), and alveolar septa (AS). 
B1–3, Soy-treated lungs showing also 
normal structure of lung structures 
on days 64, 87, and 134 of soy 
treatment. C1–3, Radiation-treated 
left lung showing thickened alveolar 
septa and clusters of IF in the vicinity 
of blood vessels (C1, C3) and infiltrat-
ing into the alveoli (C2) as seen in 
C.1A, C.2A, and C.3A enlarged areas. 
Focal areas of damaged alveoli tissues 
were replaced by a heavy infiltration 
of inflammatory infiltrates consisting 
mostly of histiocytes and lympho-
cytes (C2). D1–3, Radiation + Soy–
treated lungs showing less thickening 
of alveolar septa and less disruptions 
in lung tissue with reduced inflam-
matory infiltrates compared with 
radiation alone. All magnifications 
×20. H&E, hematoxylin and eosin; 
IF, inflammatory infiltrates.
TABLE 1.  Summary and Quantification of Histological Observations
Lung Damage IF Cells Pneumonitis Fibrosis
D64 D87 D134 D64 D87 D134 D64 D87D D134 D64 D87 D134
Control ± ± + ± ± + ± ± + ± ± +
Soy ± ± + ±± + ± ± + ± ± +
Radiation +++ +++ +++ +++ +++ +++ +++ +++ +++ + ++ +++
Rad + Soy ± ± + ± ± + ± ± + ± ± ++
Histological findings from the experience presented in Figures 4 and 5 were quantified. The extent of lung damage (disruption of alveoli, bronchioles, and vessels), IF cells, 
pneumonitis (thickened septa), and fibrosis were scaled from weak (±), moderate (+), strong (++), to heavy (+++).
IF, inflammatory infiltration.
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B1, B2; Table 1) although the staining was more intense at 
a later time point on day 134 (Fig. 5A3, B3; Table 1). Left 
lung irradiation caused an increase in collagen fibers support-
ing vessel walls and bronchioles seen on day 64 (Fig. 5C1; 
Table 1) compared with control lungs. The intensity of col-
lagen stain was further increased at later time points on days 
87 and 134 (Fig. 5C2, C3; Table 1). By day 134, an intense 
blue stain of bronchovascular bundles was clearly observed 
(Fig. 5C3; Table 1), suggesting progression of fibrosis. Lungs 
from mice treated with irradiation and soy isoflavones showed, 
within the bronchovascular bundles, an amount of collagen 
comparable with that observed in control lungs at the three 
time points tested (Fig. 5D1–D3; Table 1).
DISCUSSION
The process of lung injury caused by radiation is 
unique for this particular organ because of the clinical con-
sequences of the pathological progression of normal lung 
tissue to inflamed lung and fibrotic tissue, thereby impeding 
normal breathing functions. Radiation pneumonitis is caused 
by an early inflammatory process triggered by damage 
to lung parenchyma, epithelial cells, vascular endothelial 
cells, and stroma, which involves induction of proinflam-
matory cytokines and chemokines that recruit inflamma-
tory immune cells in the lung tissue.2,3,26,27 This acute early 
pneumonitis actually progresses to a chronic inflammation 
mediated by cyclical phases of cytokines, chemokines, and 
growth factors released in the tissue microenvironment.3,28 
These complex events culminate in the later stage of lung 
fibrosis, which result from excessive accumulation of col-
lagen and other extracellular matrix components.3,4,28 These 
adverse events of radiotherapy affect patients’ breathing and 
their quality of life.1,20,22,28
In the current study, we explored whether supplemen-
tation with natural and safe soy isoflavones could improve 
high-dose radiotherapy for inoperable NSCLC by alleviat-
ing radiation injury to normal tissues. To focus our efforts on 
dissecting the effect of soy isoflavones on radiation injury to 
FIGURE 5.  Soy inhibition of 
radiation-induced fibrosis in broncho-
vascular bundles. Lung tissue sections 
obtained on days 64, 87, and 134 
after radiation from the experiment 
described in Figure 4 were processed 
for Masson’s trichrome staining for 
detection of fibrosis. A1–3, Control 
lungs from untreated mice showing 
regular pattern of thin collagen fibers 
(stained in blue) around vessels (V) 
and bronchioles (BR) in lung tissue. 
B1–3, Lungs from soy-treated mice 
showing regular pattern of collagen 
staining like in control mice. C1–3, 
Radiation (Rad) caused a marked 
increase in density of collagen fibers 
around vessels and bronchioles in left 
lung tissues, which increased with 
time being extensive by day 134 after 
radiation. D1–3, Lung tissues treated 
with radiation and soy (Rad +Soy) 
showed normal bronchovascular col-
lagen fibers similar in density to that 
observed in control lungs on days 64 
and 87. It should be noted that by 
day 134 of the experiment the lungs 
were more congested in all treatment 
groups with a higher density of bron-
chovascular collagen fibers, however, 
there was a striking increase in fibro-
sis staining in radiation-treated lungs 
compared with control, soy, and Rad 
+ Soy–treated lungs. All magnifica-
tions ×20.
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normal lung tissue, we decided to study this complementary 
approach in naive mice not bearing tumors.
Radiation caused damage to normal hair follicles, 
leading to hair loss in the irradiated left thoracic area. 
Supplementation with soy isoflavones pre- and postradiation 
protected the majority of the mice against radiation-induced 
skin injury and hair loss or reduced the extent of hair loss. 
These original observations represent cogent evidence that 
soy isoflavones protect normal tissues from radiation-induced 
damage. Radiation-induced skin injury, probably because of 
damage to stem and progenitor cells, could progress from mild 
erythema to moist desquamation and ulceration and is still 
observed mostly in breast cancer patients as well as NSCLC 
patients because of the proximity between the skin and the 
target volume.15,29,30 Our findings on the protective effects 
of soy suggest that soy could be used to mitigate skin injury 
induced by radiation in patients. Other antioxidants includ-
ing nitroxides such as tempol have shown efficacy in reducing 
alopecia in rodents and in a few patients treated with brain 
radiotherapy.31,32 Other studies using mice showed the benefit 
of using plerixafor, a chemokine receptor type 4 antagonist, 
as a bone marrow stem cell mobilizer to improve both acute 
and late skin response to high doses of 25 to 30 Gy radiation.33
The radiation-induced acute inflammatory pneumonitis 
and late pulmonary fibrosis lead to compromised lung function 
including perfusion and gas exchange, affecting the breathing 
capacity of the patients.1,20,22,28 This phenomenon expressed by 
increased breathing rates in patients was also reported in rats 
and mice by 2 to 4 months after doses of 10 Gy or more.2,23,25 
In our studies, lung irradiation at 12 Gy caused an increase 
in breathing rate of mice, which was more pronounced by 4 
months after radiation probably because of late effects of radi-
ation-induced injury to normal lung tissue. Supplementation 
with soy isoflavones before and after radiation blocked the 
increase in breathing rate. These findings are in agreement 
with recent studies in rats showing that the genistein isofla-
vone or the superoxide dismutase catalase mimetic EUK-207 
delayed and suppressed radiation-increased breathing rate, 
confirming the radioprotective effect of genistein, which is 
the most active component of soy.24 A natural extract of soy 
isoflavones containing genistein, daidzein, and glycetein iso-
flavones was used for the current lung study because it was 
found to be more potent and safer than purified genistein.10 
The increased breathing rate caused by radiation is associated 
with pneumonitis.20 Histological observations of the left lung 
treated with 12 Gy irradiation showed the occurrence of tissue 
damage along with an inflammatory response. Irradiated lung 
tissue showed thickening of alveolar septa, which is indica-
tive of pneumonitis, as well as damage to alveolar structures, 
bronchioles, and vessel integrity. Focal hemorrhages, prob-
ably a result of vascular damage, were seen. A heavy, chronic 
infiltration of inflammatory cells consisting of histiocytes and 
lymphocytes was observed involving vessels, bronchioles, and 
alveoli. These alterations continued to progress up to the later 
time points of 3 to 4 months after radiation. Concurrently, a 
progressive increase in fibrosis was also observed in the bron-
chovascular bundles, suggesting a long-lasting and ongoing 
radiation-induced tissue damage over time. In contrast, lungs 
treated with radiation combined with soy showed milder pneu-
monitis and reduced fibrosis. A decrease in fibrosis caused by 
genistein or EUK-207 was also observed in irradiated lungs of 
naive rats that could be associated with antioxidant and anti-
inflammatory mechanisms involving inhibition of transform-
ing growth factor-β1 expression, which is a major fibrogenic 
cytokine.4,24
Taken together, these observations confirm that soy 
isoflavones can modulate the inflammatory response caused 
by radiation and slow down the progressive tissue damage 
induced by radiation, which leads to impaired lung function. 
These findings in naive mice are in agreement with our find-
ings on radioprotection of normal lung tissues in the A549 
lung tumor model7 and demonstrate that soy can protect 
against radiation-induced injury to normal lung tissue. In 
our studies, the levels of isoflavones measured in the serum 
of mice treated with soy isoflavones reflected typical in vivo 
metabolism with significant levels of daidzein (1.6 μM) and 
genistein (1.7 μM).10 These levels are comparable with plasma 
concentrations of 1 to 4 μM soy isoflavones measured in 
Asian populations consuming foods rich in soy isoflavones, in 
contrast to 10 to 30 nM levels found in Western populations.14
Several studies on radioprotectors and mitigators to 
minimize radiation toxicity are ongoing and include radical 
scavengers and antioxidants, some of which such as amifos-
tine, tempol, and melatonin have been clinically tested.20,32 
However, limitations include their safety and tumor pro-
tection from radiation effect. The use of soy isoflavones as 
radioprotectors is attractive because they were proven to be 
safe in controlled human clinical trials.5 Our experimental 
studies in animal models suggest that the addition of soy to 
radiotherapy might improve the effect of radiotherapy on the 
tumor target and reduce the dose-limiting toxicity of radio-
therapy to the normal lung. If this proves to be the case, this 
simple, nontoxic, natural compound would radically improve 
the effectiveness of this new radiation treatment for inoper-
able NSCLC.
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